CClinicalTrials.gg
CompletedNCT02599181Updated May 31, 2017

Local Inflammation Does Not Correlate With Bacterial Colonization and Contamination of Perineural Catheters

An interventional study of propanol-biphenol: Kodan in Catheter Infection, sponsored by Balgrist University Hospital. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-31.

Sponsored by Balgrist University Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study was to investigate the influence of alcoholic skin disin-fection before PNC (perineural catheter)-removal on the detection of bacteria on the subcutaneous part of the PNC or on the tip. Furthermore, the correlation of bacterial colonization with PNC-associated local inflammation or infection was evaluated.

Read the detailed description

Two hundred orthopedic patients planned to receive a PNC are prospectively randomized to group PNC-removal with alcoholic skin disinfection or group PNC-removal without skin disinfection.

After standardized PNC-placement under sterile conditions, patients receive a perioperative antibiotic prophylaxis and clinical signs of local inflammation or infection are periodically recorded: The PNC were observed twice daily for clinical signs of local inflammation and local infection. Patients were also evaluated for clinical signs of systemic infection. The adhesive dressing was changed only if it became dislodged or if blood or secretions made visualization of the puncture site impossible. For the dressing change, the anaesthesiologist wore a facemask, a cap and sterile gloves.

Postoperatively, 6 hours after the initial bolus, a local anaesthetic infusion line was connected to the micro filter of the PNC. All patients received patient-controlled perineural analgesia (basal rate 5 ml/h, bolus 4 ml, lock-out time 20 min) with ropivacaine 0.3% for 24 hours, and then reduced to ropivacaine 0.2%.

PNC were removed under sterile conditions after 72h or earlier in the case of signs of infection: Removal of the PNC was performed on the surgical ward by an anaesthesiologist according to a standardized procedure: Wearing a facemask and a cap, the adhesive skin dressing was removed. In the "WITH-group", the skin was now disinfected with an aerosolized alcoholic solution (propanol-biphenol). Procedure continued after three minutes, when the skin was dry with the anaesthesiologist wearing sterile gloves and using sterile tweezers.

The distal part of the PNC (directed to the tip of the PNC) was withdrawn for 1 cm at the insertion site and then cut distally from the tweezers with a sterile pair of scissors. The distal part of the PNC was then totally withdrawn with the sterile tweezers, and with the sterile pair of scissors cut in two parts: the tip (defined as the most distal 2 cm) and the subcutaneous part, which were placed in separate dry sterile containers.

Finally, the remaining proximal part of the PNC was thrown away.

The sterile containers containing the PNC were stored at 4°C and were sent to the laboratory the same day for microbiological analysis of the PNC: The PNC were rolled onto sheep blood agar plates (Becton Dickinson BD, Basel, Switzerland) similar to the semiquantitative culture method for intravenous catheters [10] and thereafter immediately transferred to a liquid enrichment medium (thioglycolate medium, BD Basel Switzerland). Sheep blood agar was incubated for 2 days and thioglycolate for 5 days. In case of growth in the enrichment media only, an aliquot of the liquid was subcultured on solid media. Reports were considered to be positive if any growth was present. Identification of the isolated bacteria and susceptibility testing were performed according to standard methods.

All patients were observed for clinical signs of local infection at the PNC insertion site and for clinical signs of systemic infection one week after PNC-removal. For the correlation of the detection of bacteria on the PNC with clinical signs of in-flammation, the sensitivity, specificity, positive and negative predictive values were calculated on the basis of the following three categories: 1) any growth of bacteria including enrichment, 2) more or equal 5 colonies and 3) more or equal 15 colonies with the semiquantative culture technique, respectively.

02

Conditions studied

  • Catheter Infection

Browse trials for

Keywords

  • Perineural cathether
  • Catheter infection
03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

This study's enrollment of 200 is above the median of 50 across 2,437 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Balgrist University Hospital is the lead sponsor of 80 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Written informed consent, surgery with perineural catheters

Exclusion criteria

Exclusion criteria:

diabetes mellitus, medication with immunosuppressant drugs or any other immune-compromising illness

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    WITH-Group: alcoholic skin disinfection

    In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland prior to perineural catheter removal.

    Other: propanol-biphenol: Kodan

  • No intervention
    WITHOUT: no alcoholic skin desinfection

    In the "WITHOUT-group", the skin is NOT disinfected prior to perineural catheter removal.

Interventions

  • Otherpropanol-biphenol: Kodan

    WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke \& Mayr, Zurich, Switzerland.

06

What researchers measure

Primary outcomes

  1. Bacteria detection

    The reduction of the PNC-colonization rate depending on the removal technique (with or without previous skin disinfection)

    Time frame: After removal of PNC 72h after its insertion

Secondary outcomes

  1. sensitivity: to measure the proportion of positives that are correctly identified as such (the percentage of colonized catheters which clinically show an infection). Sensitivity = all clincally positive / all catheters (no unit)

    correlation between the Perineural-colonization and clinical signs of local inflammation at the puncture site

    Time frame: After removal of PNC 72h after its insertion until one week after PNC-removal

  2. Specifity: measures the proportion of negatives that are correctly identified as such (the percentage of not colonized catheters which clinically do not show an infection). Specifity = all clinically negative / all catheters (no unit)

    correlation between the Perineural-colonization and clinical signs of local

    Time frame: After removal of PNC 72h after its insertion until one week after PNC-removal

  3. negative predictive value: all testing negative and no clinical signs of local infection / all testing negative (no unit)

    correlation between the Perineural-colonization and clinical signs of local

    Time frame: After removal of PNC 72h after its insertion until one week after PNC-removal

  4. Positive predictive value: all testing positive and with clinically infection / all testing positive (no unit)

    correlation between the Perineural-colonization and clinical signs of local

    Time frame: After removal of PNC 72h after its insertion until one week after PNC-removal

07

Study locations

1 site
  • Balgrist University Hospital
    Zurich, 8008, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02599181
Lead sponsor
Balgrist University Hospital
Collaborators
University Hospital, Zürich
Responsible party
Sponsor
First posted
Nov 6, 2015
Start date
Jan 2013
Primary completion
Jan 2014
Completion
May 2014
Last update
May 31, 2017

Study contacts

Alain Borgeat, Prof. MD
study director · Balgrist University Hospital, Zurich

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion